Preoperative combination chemotherapy improved survival in pancreatic cancer

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Neeha Zaidi, MD, is turning the tables on pancreatic cancer. Mutations to a gene called KRAS—a cancer driver common to almost all pancreatic cancers—are now a target for prevention and treatment.

October 30, 2026

Vol.52 No.40

By Valerie Mehl

Conversation with The Cancer Letter

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P.

October 23, 2026

Vol.52 No.39

Obituary

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

Rachna Shroff, a physician-scientist who spent much of her career researching treatments for pancreatic and biliary cancers, has died at the age of 47. She briefly battled an aggressive cancer of an unknown origin.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

Clinical Regulatory News

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

For the past four decades, psilocybin research has focused on one area: the treatment of mental health disorders, including depression, anxiety, existential distress associated with serious medical illnesses, post-traumatic stress disorder, and addiction.

October 02, 2026

Vol.52 No.36

By Sara Willa Ernst

Preoperative combination chemotherapy improved survival in pancreatic cancer

YOU MAY BE INTERESTED IN

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

Renew today!

Subscriber content

Never miss an issue!

Login

Preoperative combination chemotherapy improved survival in pancreatic cancer

YOU MAY BE INTERESTED IN

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53Shokat was named 2026 Stephenson Global Prize winner

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47Her endowed award will live on

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy“Because it works in one neural system, you begin to wonder: Well, what about another?”

Never miss an issue!

Login

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”